Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

European Innovation Council · Running

PERFORM Perovskite Photon Counting X-ray Detectors for Medical Imaging.

Coordinator
Clarity Sensors Limited, United Kingdom
Runs
1 June 2025 to 31 May 2028
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101214552

What the project is doing

In the project's own words, from its summary on CORDIS.

X-ray imaging is a crucial diagnostic tool in modern medicine, with 3.6B examinations performed annually. However, X-rays are carcinogenic and pose health risks if not carefully managed. Current detectors used in X-ray imaging and CT scanners prevent advances in image resolution and reduction in radiation dose, limiting screening programs and early disease detection. Photon-counting CT (PCCT) systems, which have recently entered the market, offer significant health benefits and present a promising path toward more widespread preventative imaging.

However, the adoption of PCCT technology has been slow, primarily due to the energy-intensive and complex fabrication processes of first-generation materials. There is an urgent need for next-generation photon-counting detectors (PCDs) that can reduce radiation dose, improve image resolution, and streamline manufacturing. Clarity Sensors, a University of Cambridge spin-off, is developing advanced PCDs with halide perovskite semiconductors.

Our patented monolithic integration process, combined with leading perovskite quality, positions Clarity Sensors to deliver industry-leading PCDs, targeting the highest image resolution and lowest effective dose, enabling 100 times more scans at the same radiation level. Through projects such as our ERC Proof-of-Concept (PEROVSCI), we have demonstrated a stable, single-pixel halide perovskite PCD and filed key IP culminating in the fabrication of the first monolithic perovskite PCD on a multi-pixel ASIC.

In PERFORM, we will further develop our technology and business operations to position Clarity Sensors for investment and joint development. This will include optimising our current PCD systems and developing our working demonstrator, PRISM-X, which will be validated against commercial technologies in clinical settings to reach TRL5. Additionally, we will expand our technical and commercial team, secure additional IP, engage target customers, and initiate joint-development agreements.

Topics

Who is involved

OrganisationCityCountryRole
Clarity Sensors LimitedCambridgeUnited KingdomCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI